Refana

News

  • Home
  • Programs
    • AI in Medicine
    • Vaccines
    • Early Cancer Detection
  • Corporate
  • Team
  • About
  • Blog
    • News
    • COVID Industry Updates

5/18/2022

Why Artificial Intelligence Creates an Unprecedented Era of Opportunity in the Near Future

0 Comments

Read Now
 
Picture

After several long "winters," business is ready for an A.I. spring.

The age of artificial intelligence (A.I.) is finally upon us. Consumer applications of A.I., in particular, have come a long way, leading to more accurate search results for online shoppers, allowing apps and websites to make more personalized recommendations, and enabling voice-activated digital assistants to better understand us.

As impressive as these uses of A.I. are, they only hint at how this game-changing technology will be applied in business. Because the goal of business A.I. is to help the companies that drive our global economy learn from their data to become vastly more resilient, adaptive, and innovative.

We all know there is tremendous potential value in data, which continues to grow exponentially. In fact, the world is creating 2.5 quintillion bytes of data every day (that's 2.5 followed by 18 zeros). To harness that potential, companies need A.I. to make sense of the data, and hybrid cloud computing platforms that can distribute it across organizations.

​The economic opportunity behind these technologies is enormous, given that business is only about 10 percent of the way to realizing A.I.'s full potential.

By Arvind Krishna, Chairman and Chief Executive Officer, IBM

​Read the full article here.

Back to Blog

Share

0 Comments

5/12/2022

World complacent on Covid, warns former UK prime minister Gordon Brown

0 Comments

Read Now
 
Picture
By Naomi Grimley
Health Correspondent

Gordon Brown has warned that the world risks "sleepwalking" into another Covid variant crisis if it does not increase vaccinations in low-income countries.

Wealthier countries needed to share the cost of global vaccinations, tests and treatments, he told the BBC.

Speaking before an international Covid summit on Thursday, the former UK prime minister said the world had become "complacent" about the virus.

US President Joe Biden is due to host the virtual summit at the White House.

He does so at a time when Congress has failed to approve key funds earmarked for the global pandemic response.

Campaigners fear that could mean other countries will not offer extra money either, leaving the push for better vaccine coverage around the world without momentum.

Mr Brown, who is a World Health Organization (WHO) ambassador on health finance, said the numbers were "shocking".

"Only 11% have been vaccinated in low-income countries and we set a target of 70%," he said.
"Tragically, we are sleepwalking into the next variant, and political leaders are still not listening to the medical advice that is still there - that we've got to increase vaccination, continue to test at a high level, and provide the new treatments available."

​Read the full article here.
​

Back to blog

Share

0 Comments

5/6/2022

AI can detect breast cancer signs that radiologists don’t see, new study finds

0 Comments

Read Now
 
Euro News
Artificial intelligence (AI) is showing promising results in detecting breast cancer which may otherwise have been missed by radiologists, the largest study of its kind has found.

Researchers in Germany discovered that AI can correctly detect interval breast cancers, which develop in between routine screening rounds (usually 24 months in many countries) and can be missed and diagnosed as a false negative result.

In 2020, there were 2.3 million women diagnosed with breast cancer and 685 000 deaths globally, according to the World Health Organization (WHO).

The peer-reviewed study showed approximately 16 per cent of interval cancers are probably visible during a previous screening while one in five may be too subtle to the human eye and can be missed by radiologists, which is known as "minimal signs".

The findings present an opportunity to detect more cancers at a screening with AI, which may help detect breast cancer earlier.

​Read the full article here.
Back to Blog

Share

0 Comments

4/23/2022

Population-wide study of COVID-19 vaccination shows that mix-and-match approach to booster vaccination offers the best protection

0 Comments

Read Now
 
Picture
A new study on Chile’s national COVID-19 vaccination program, to be presented at this year’s European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022, Lisbon 23-26), and published in The Lancet Global Health, shows that giving a different type of vaccine (heterologous) for the third or ‘booster’ dose than was received for the first two doses, leads to better vaccine performance than using the same (homologous) inactivated SARS-CoV-2 vaccine for all three doses.
The study is by Dr Rafael Araos, Institute of Science and Innovation in Medicine, Clinica Alemana, Universidad del Desarrollo, Dr Alejandro Jara, and Dr Eduardo A Undurraga from Pontificia Universidad Católica de Chile, and colleagues including Dr  Johanna Acevedo  from the Chilean Ministry of Health.

The study assesses the effectiveness of CoronaVac (Sinovac Biotech), AZD1222 (Oxford-AstraZeneca), or BNT162b2 (Pfizer-BioNTech) vaccine boosters in individuals who had completed a primary two-dose immunisation schedule with CoronaVac, an inactivated SARS-CoV-2 vaccine which accounts for about half the COVID-19 vaccine doses delivered globally, compared with no vaccination. The study assessed the nationwide vaccination program in Chile, where the two-dose Coronavac schedule was by far the most commonly given. 

Individuals administered vaccines from Feb 2, 2021 to the prespecified trial end date of Nov 10, 2021 were evaluated; the team excluded individuals with a probable or confirmed SARS-CoV-2 infection (RT-PCR or antigen test) on or before Feb 2, 2021, and individuals who had received at least one dose of any COVID-19 vaccine before Feb 2, 2021. They estimated the vaccine effectiveness of booster doses against laboratory-confirmed symptomatic COVID-19 (symptomatic COVID-19) cases and COVID-19 outcomes (hospitalisation, admission to the intensive care unit [ICU], and death).

A total of 11 174 257 individuals were eligible for this study, among whom 4 127 546 completed a primary immunisation schedule (two doses) with CoronaVac and received a booster dose during the study period. 1 921 340 (46·5%) participants received a heterologous AZD1222 booster, 2 019 260 (48·9%) received a heterologous BNT162b2 booster, and 186 946 (4·5%) received a homologous booster with CoronaVac.

The authors calculated an adjusted vaccine effectiveness (using statistical modelling) in preventing symptomatic COVID-19 of 79% for a two-dose schedule plus CoronaVac booster, 97% for a BNT162b2 booster, and 93% for an AZD1222 booster. The adjusted vaccine effectiveness against COVID-19-related hospitalisation, ICU admission, and death was 86%, 92%, and 87% for a CoronaVac booster, 96%, 96%, and 97% for a Pfizer-BioNTech booster, and 98%, 99% and 98% for an Astra Zeneca booster.

​Read the full article here.

Back to blog

Share

0 Comments

3/22/2022

Experts assumed China needed an mRNA COVID vaccine to reopen safely. New data suggest that may not be the case

0 Comments

Read Now
 
Picture
China’s inactivated Sinovac COVID vaccine may provide as much protection from death as Germany’s BioNTech mRNA jab after three doses, according to new research from Hong Kong University. The findings suggest that China, which continues to impose tough COVID-zero policies, may not need to approve or develop mRNA vaccines to emerge from the pandemic.

​
Read more.

Picture
Hong Kong Free Press announced:
​
During the press conference, HKU’s medical faculty released its latest empirical analysis of the effectiveness of the two available vaccines – the Chinese-made Sinovac and German-produced BioNTech – based on data of hospitalised patients in Hong Kong as of March 8.

According to their findings, receiving three jabs of a Covid-19 vaccine, irrespective of the brand, can provide around 98 per cent of immunity against severe or fatal cases in patients aged 60 or above.

​Read more.

Back to Blog

Share

0 Comments

1/25/2022

How Can Artificial Intelligence Change Medical Imaging?

0 Comments

Read Now
 
Health IT

​Artificial intelligence can improve medical imaging for screenings, precision medicine, and risk assessment. 
​

Increasingly, researchers are looking for ways to implement artificial intelligence into medical imaging.
There are several different cases for why a patient might need medical imaging. Whether it’s for a cardiac event, fracture, neurological condition, or thoracic complications, AI can quickly diagnose and provide treatment options.

Recently, research organizations and universities have been pursuing the expansion of AI in cancer screenings. Due to the COVID-19 pandemic, many patients chose to delay care, such as well-visits and cancer screenings, resulting in more advanced cancers.
​
By implementing AI into medical imaging, the technology can enhance medical screenings, improve precision medicine, assess patient risk factors, and lighten the load for physicians.

This article looks at how AI can help in:
  • Advancing Medical Screenings - By using AI in medical imaging, physicians can identify conditions much quicker, promoting early intervention.
  • Improving Precision Medicine - AI can also be implemented into medical imaging to advance precision medicine. 
  • Indicating and Assessing Risk - While AI can be used in medical imaging to identify current conditions impacting a patient, it can also predict the potential risk for future illnesses.

Read the full article here.​
Back to Blog

Share

0 Comments

12/28/2021

SARS-CoV-2 spike T cell responses induced upon vaccination or infection remain robust against Omicron

0 Comments

Read Now
 
Picture
The SARS-CoV-2 Omicron variant has multiple Spike (S) protein mutations that contribute to escape from the neutralizing antibody responses, and reducing vaccine protection from infection. The extent to which other components of the adaptive response such as T cells may still target Omicron and contribute to protection from severe outcomes is unknown. We assessed the ability of T cells to react with Omicron spike in participants who were vaccinated with Ad26.CoV2.S or BNT162b2, and in unvaccinated convalescent COVID-19 patients (n = 70).

We found that 70-80% of the CD4 and CD8 T cell response to spike was maintained across study groups. Moreover, the magnitude of Omicron cross-reactive T cells was similar to that of the Beta and Delta variants, despite Omicron harbouring considerably more mutations. Additionally, in Omicron-infected hospitalized patients (n = 19), there were comparable T cell responses to ancestral spike, nucleocapsid and membrane proteins to those found in patients hospitalized in previous waves dominated by the ancestral, Beta or Delta variants (n = 49).

These results demonstrate that despite Omicron’s extensive mutations and reduced susceptibility to neutralizing antibodies, the majority of T cell response, induced by vaccination or natural infection, cross-recognises the variant. Well-preserved T cell immunity to Omicron is likely to contribute to protection from severe COVID-19, supporting early clinical observations from South Africa.

​Read the full paper here.


Back to Blog

Share

0 Comments

11/27/2021

Could WIV Vaccines hold the key to beating the new super strain

0 Comments

Read Now
 
Picture
By ETHAN ENNALS FOR THE MAIL ON SUNDAY

​
Experts told The Mail on Sunday that there is one jab ready to go that might already be highly effective against this version of the virus: the one developed by French firm Valneva and ordered by the UK Government – but then cancelled.
​

It could have an advantage over current jabs because the way it’s been made differs.

It contains what is known as a fully inactivated virus – a whole Covid virus that has been neutralised. 
Though it can’t cause illness, the immune system reacts by recognising the threat and creating antibodies and other fighter cells, enabling the body to fight off the real virus if it becomes infected.

​Other shots such as Pfizer and AstraZeneca use genetic fragments from one part of the Covid virus, called the spike protein – the section that allows it to bind with healthy cells.

It is this part that’s prone to mutations: the 32 mutations seen in the Botswana variant are all found on the spike protein, which increases the chances that the antibodies developed in response to the above vaccines may not ‘recognise’ it, allowing the virus to slip past.

Since the Valneva jab has more parts of the virus for the immune system to learn from, experts believe it could be more ‘variant-proof’ than the others.

Professor Adam Finn, paediatrician and member of the Joint Committee on Vaccination and Immunisation, the Government’s advisory group, says there is a ‘strong theoretical argument’ that the Valneva jab could provide protection against the Botswana variant. 

‘This is potentially a more resilient vaccine,’
he said. 

‘Obviously we’d need to look at how it reacts to this particular variant but I think there’s a strong argument for doing that right now.’
​
Trial results published last month found two doses of Valneva were 95 per cent effective at preventing infection. The trial of 4,000 participants also reported no cases of severe illness.
​
Read the full article

Back to Blog

Share

0 Comments

10/6/2021

Private clinics in Singapore seeing demand for Sinovac and Sinopharm Covid-19 vaccines as booster shots

0 Comments

Read Now
 
Picture
SINGAPORE: Several private clinics here have been seeing a demand for Sinovac and Sinopharm vaccines as booster shots, owing largely to a fear of side effects from the third dose of an mRNA jab.
Vaccines like Sinovac and Sinopharm use inactivated viral particles to teach one's immune system to make antibodies.

So far, it has been recommended that those aged 50 and above take an additional mRNA shot of either the Pfizer-BioNTech or Moderna vaccines at least six months after their two-dose vaccine regimen, to ensure a high level of protection from severe disease is maintained across a longer period.
The Expert Committee on Covid-19 Vaccination is still studying the possibility of mixing vaccines for the booster dose.

Dr Chua Guan Kiat, a general practitioner at Chua Medical Clinic and Surgery in Bukit Batok, told The Straits Times that there has so far been a "sizeable demand" for Sinovac and Sinopharm as vaccine boosters, the bulk of which comes from the elderly who had been fully vaccinated with an mRNA vaccine.

Since his clinic started offering Sinovac jabs on Sept 23, Dr Chua said that 20 to 30 doses of booster vaccine are being administered each day, with demand likely to rise steadily now that those over 50 have also been invited to take their booster doses.
​
He added that the fear of potential side effects from a third dose of the mRNA vaccine has been a major driving force to opt for an inactivated vaccine like Sinovac as a booster.

"Anecdotally, many who had one dose of the inactivated vaccine after receiving two doses of the mRNA had very good antibody results. No doubt, the best antibody results were still obtained with a third mRNA dose, but many didn't want to go through the same side effects again," he said.
​
One of his customers, Mr Ho, who is in his 60s, recently received his Sinopharm booster jab after two doses of the Pfizer vaccine.

Asked why he had opted for Sinopharm instead of an mRNA vaccine, Mr Ho said he felt the Sinopharm vaccine uses a tried-and-tested inactivated virus technology, whereas the mRNA technique was previously used to help stimulate antibody response in patients with late-stage cancers.

Mr Ho, who declined to give his full name and his occupation, said the long-term effects of mRNA still remain unknown.

He told ST that he experienced severe pain at his injection site after his second Pfizer dose but not after his Sinopharm booster.

​Read the full article here.

Back to Blog

Share

0 Comments

10/5/2021

Australia approves CoronaVac and Covishield and opens the way for the entry of thousands of vaccinated foreigners

0 Comments

Read Now
 
Picture
CANBERRA — Australia has approved CoronaVac and Covishield vaccines, allowing travelers and foreign students immunized with them to enter the country. As the national immunization rate approaches 80% of the population vaccinated with at least one dose and 45.6% with both, Canberra will begin in November to eliminate one of the strictest border controls imposed in the world to contain the Covid-19 pandemic.

CoronaVac, from the Chinese laboratory Sinovac, is one of the most used anti-Covid vaccines worldwide, with applications from Indonesia to Brazil and Turkey. CoviShield is the version of the vaccine from the University of Oxford and the AstraZeneca laboratory produced by the Serum Institute of India, the world’s largest manufacturer of vaccines. Australia uses Pfizer, Moderna and AstraZeneca vaccines in its campaign, so travelers who have taken these immunizations will also be free to enter the country.


The announcement, made on Friday, opens the door to thousands of foreign students who were excluded from Australia during the pandemic as, according to the main Australian drug regulator, the Therapeutic Goods Agency, the entry of immunized travelers into the country it will only be released to people who have received “nationally recognized vaccines”.
​
“Very soon, we can open international borders again,” said Prime Minister Scott Morrison. “This will start to happen from next month.

Read the full article here.

Back to Blog

Share

0 Comments
<<Previous
Details

    Categories

    All
    Artificial Intelligence
    Covid 19
    Early Cancer Detection
    Press Release

    Archives

    May 2022
    April 2022
    March 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    July 2020
    June 2020

    RSS Feed

​Practical Solutions for complex and ​urgent global medical problems

HOME     |     PROGRAMS    |    TEAM     |     ABOUT     |     NEWS
Privacy Policy | Cookie Policy
© 2022 Refana Inc
  • Home
  • Programs
    • AI in Medicine
    • Vaccines
    • Early Cancer Detection
  • Corporate
  • Team
  • About
  • Blog
    • News
    • COVID Industry Updates